Jan 12, 2021 Cellectar Initiates Pivotal Trial of CLR 131 in Waldenstrom’s Macroglobulinemia Learn More
Dec 28, 2020 Cellectar Biosciences Announces Closing of $24.5 Million Underwritten Public Offering and $20.5 Million Concurrent Private Placement Learn More
Dec 23, 2020 Cellectar Biosciences Announces Pricing of $24.5 Million Underwritten Public Offering and $20.5 Million Concurrent Private Placement Learn More
Dec 22, 2020 Cellectar Biosciences Announces Proposed Underwritten Public Offering and Concurrent Private Placement Learn More